Editas Medicine Revenue and Competitors
Estimated Revenue & Valuation
- Editas Medicine's estimated annual revenue is currently $24.5M per year.
- Editas Medicine received $50.0M in venture funding in December 2017.
- Editas Medicine's estimated revenue per employee is $90,369
- Editas Medicine's total funding is $656.6M.
- Editas Medicine's current valuation is $1.5B. (January 2022)
Employee Data
- Editas Medicine has 271 Employees.
- Editas Medicine grew their employee count by -5% last year.
Editas Medicine's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Process and Analytical Development | Reveal Email/Phone |
2 | VP Financial Planning Analysis | Reveal Email/Phone |
3 | VP, Intellectual Property | Reveal Email/Phone |
4 | SVP | Reveal Email/Phone |
5 | EVP, CTO and CBO | Reveal Email/Phone |
6 | VP, Head Genetics and Genomics | Reveal Email/Phone |
7 | Head In Vivo Regulatory Affairs | Reveal Email/Phone |
8 | SVP Operations Editas Medicines | Reveal Email/Phone |
9 | VP Finance and Corporate Controller | Reveal Email/Phone |
10 | VP, Associate General Counsel and Asst. Secretary | Reveal Email/Phone |
Editas Medicine Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $92.1M | 501 | 0% | $127M | N/A |
What Is Editas Medicine?
Unlocking the Promise of Genome Editing to Deliver Life-Changing Medicines. As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$656.6M
Total Funding
271
Number of Employees
$24.5M
Revenue (est)
-5%
Employee Growth %
$1.5B
Valuation
N/A
Accelerator
Editas Medicine News
Editas Medicine Inc. said the U.S. Food and Drug Administration granted rare pediatric disease designation to EDIT-301, an investigational,...
Amid chaos comes good newsEditas Medicine has received Rare Pediatric Disease designation from the FDA for its gene-edited medicine EDIT-301 to treat...
CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced...
Editas’s stock fell more than 20 percent on the Nasdaq Tuesday morning following the announcement. The news dragged other gene-editing shares down as well. Switzerland-based Crispr Therapeutics’ shares, which also trade on the Nasdaq, fell more than 13 percent, while Cambridge-based Intellia The ...
CAMBRIDGE, Mass., Dec. 21, 2018 (GLOBE NEWSWIRE) — Editas Medicine, Inc.(NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Financial Officer, Andrew Hack, M.D., Ph.D., will be stepping down from the Company, effective March 1, 2019, to return to the investment indus ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $79.8M | 275 | -1% | $3M |
#2 | $81.7M | 275 | -18% | N/A |
#3 | $62.8M | 278 | 47% | $240.8M |
#4 | $15M | 281 | 31% | $5.8M |
#5 | $31.5M | 281 | 6% | N/A |
Editas Medicine Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2017-12-07 | $50.0M | Undisclosed | Morgan Stanley | Article |